Abstract: The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-? (Pgd1?) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.

Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.

Abstract: The present invention relates to a pharmaceutical composition comprising glycerol esters of a fatty acid, wherein the compositions are useful for the delivery of anti-psychotic drugs.

Abstract: Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The formulation according to the invention has a shelf-life of up to 24 months or more.

Abstract: This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably ?-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.

Abstract: Described is a class of symmetrical and asymmetrical N-alkyl lactam ethers. One preferred ether is bis-N-ethyl pyrrolidone ether. Preferred compositions and uses of the ethers are in performance chemicals, personal care, and pharmaceutical fields, where they function a variety of roles, including as a solvent, solubilizer, freezing point depressor, diluent, extracting agent, cleaning agent, degreaser, absorbent and/or dispersion agent.

Abstract: There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex.

Abstract: There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex.

Abstract: A therapeutic method for attenuating symptoms of inflammation and autoimmune diseases. This method includes preparing and administering to animals intraperitoneally or orally a metallic gold cluster complex preparation.

Abstract: A novel delivery system for drugs, and especially macromolecules such as proteins or oligonucleotides through biological membranes is provided, and specifically delivery of siRNA. The delivery system comprises conjugation of the macromolecule drug to a moiety that enables effective passage through the membranes. Respectively, novel compounds and pharmaceutical compositions are provided, utilizing said delivery system. In one aspect of the invention, the compounds may be utilized in medical practice, for example, in delivery of siRNA or antisense oligonucleotides across biological membranes for the treatment of medical disorders.

Abstract: A blood brain barrier shuttle comprising a brain effector entity and a brain targeting peptide.

Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.

Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

Abstract: The present invention provides antibodies or antigen-binding fragments thereof that specifically bind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.

Abstract: Provided are methods of use of compounds comprising a self-immolative group, which compounds may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Abstract: Provided is a pharmaceutical preparation composition comprising a polymerized camptothecin derivative which is obtained by bonding a camptothecin derivative to a polymer carrier, and has nanoparticle-forming properties of associating in an aqueous solution, the pharmaceutical preparation composition having enhanced preparation stability. Particularly, a pharmaceutical preparation maintaining nanoparticle-forming properties, which are an important factor, and having an excellent storage stability is provided. Disclosed is a pharmaceutical preparation comprising a block copolymer in which a polyethylene glycol segment is linked to a polyglutamic acid segment containing a glutamic acid unit having a camptothecin derivative bonded thereto, the pharmaceutical preparation capable of forming associates in an aqueous solution. When the pharmaceutical preparation is made into an aqueous solution containing the camptothecin derivative at a concentration of 1 mg/mL, the pH of the aqueous solution is 2.4 to 7.

Abstract: Disclosed are PARP-1 inhibitors, which can be 18F-labeled for use as tracers in positron emission tomographic (PET) imaging. Further disclosed are methods of synthesis. Of the compounds synthesized, 2-[p-(2-Fluoroethoxy)phenyl]-1.3.10-triazatricyclo[6.4.1.04,13]trideca-2,4(13),5,7-tetraen-9-one (12) had the highest inhibition potency for PARP-1 (IC50=6.3 nM). Synthesis of [18F]-12 is disclosed under conventional conditions in high specific activity with 40-50% decay-corrected yield. MicroPET imaging using [18F]-12 in MDA-MB-436 tumor-bearing mice demonstrated accumulation of [18F]-12 in a tumor. Binding, can be blocked by olaparib. The compounds have utility for tumor imaging.

Abstract: An ultraviolet (UV) light sanitizing system is configured to sanitize a structure. The UV light sanitizing system includes a UV light assembly that is configured to emit UV light onto the structure, and a UV light emission control unit coupled to the UV light assembly. The UV light emission control unit is configured to control the UV light assembly to emit UV light onto the structure within at least a first UV band and a second UV band that differs from the first UV narrow band during a sanitizing cycle that sanitizes the structure. The UV light within the first and second UV bands is configured to kill at least one type of microbe.

Abstract: An apparatus for sanitizing a stethoscope head. The apparatus includes a housing, a reservoir disposed within the housing for containing the sanitizing fluid, one or more applicator pads mounted on the housing, and a dispensing valve for dispensing the sanitizing fluid from the reservoir onto the applicator pad.

Abstract: A combination of herbal extracts in aqueous solution that when sprayed into a confined area as a fine mist, chemically neutralizes a wide range of odors including those that are acidic, alkaline, and neutral in nature. While this chemical solution may contain fragrances, odor elimination occurs chemically rather than by masking.

Abstract: A method of delivering a volatile material to the atmosphere in a continuous manner is disclosed. The method includes providing a delivery engine having a reservoir that includes a volatile material mixture. The volatile material mixture includes about 40% to about 100%, by total weight, of the volatile materials each having a vapor pressure at 25° C. of less than about 0.1 torr. The delivery system also includes a microporous membrane enclosing the reservoir, wherein the microporous membrane comprises an average pore size of about 0.01 to about 0.03 microns.

Abstract: Devices and methods relate to inducing or promoting hemostasis. The hemostasis device may include a support layer having a first surface and an opposing second surface. The device may include a layer, the layer disposed on the first surface. The layer may include a target surface configured to contact a target site. The layer may include a monolayer of about 100% graphene or may include laser-reduced graphene oxide. The device may include a sensor configured to measure a level of hemostasis of the target site. The methods relate to a method of manufacturing a hemostatic device including a monolayer of graphene or a layer of laser-reduced graphene oxide.

Abstract: Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.

Abstract: The inventions provided herein relate to dissolvable hydrogel compositions and methods of uses, e.g., but not limited to, in wound management. Accordingly, methods for wound management involving the dissolvable hydrogel compositions are also provided herein. In some embodiments, the dissolvable hydrogel composition comprises an adhesive thioester hydrogel, which can facilitate adherence of the dissolvable hydrogen composition to a surface (e.g., a wound) and can be controllably dissolved later upon addition of a thiolate compound to release the dissolvable hydrogel composition from the surface (e.g., the wound).

Abstract: The present invention relates to compositions in the form of oil-in-water dispersions comprising a silicone oil having an average droplet diameter from about 30 microns to about 2000 microns and a polymeric thickening agent. These compositions are useful for stimulating collagen production in human patients and other mammals, and have applications for soft tissue augmentation for various medical and cosmetic procedures. The present invention also relates to methods for preparing these compositions and to methods for stimulating collagen production in human patients and other mammals in need thereof. In contrast to the prior art, the compositions and methods of the present invention are particularly useful for stimulating the production of high quality collagen that is uniform, smooth, long-lasting, and having good structural integrity.

Abstract: Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant.

Abstract: Osteogenic compositions include a decellularized extracellular matrix tissue and bone morphogenic protein, preferably BMP-2. The compositions make beneficial use of the BMP, which can be used at relatively low doses and can bind to native components (e.g., native sulfated glycosaminoglycans such as heparin and/or heparan sulfate) remaining in the decellularized extracellular matrix tissue. Methods for preparation and use of such compositions are also described. The compositions and related methods can be used in the treatment of diseased or damaged bone tissue.

Abstract: A method for producing an engineered tissue scaffold for neural repair is described. The method includes tethering a hydrogel matrix seeded with tension-generating cells to a frame, and allowing the tension-generating cells to generate tension within the matrix, such that the cells self-align. The matrix may then be at least partially dehydrated to form a sheet. The tension-generating cells are stem cells capable of differentiating into cells having Schwann-cell-like properties, or are derived from such stem cells. In preferred embodiments, the cells are neural stem cells, for example conditionally immortalized neural stem cells of fetal cortex origin.

Abstract: A stent, the stent including a first coating composition disposed on at least a portion of the outer surface of the stent, the first coating composition having at least one bioadhesive and a second coating composition disposed over the first coating composition, the second coating composition having at least one biodegradable polymer, and methods of making and using the same.

Abstract: Method are disclosed for local and systemic administration HDL, recombinant HDL or HDLm for the prevention, treatment, or amelioration of a vascular disorder, disease or occlusion such as restenosis or vulnerable plaque.

Abstract: An aspiration device is described, including a bulb aspirator including a bulb body, a first collar and tip, the bulb body includes an upper portion configured for receiving one end of the first collar and lower portion configured for receiving in a first configuration a stop and in a second different configuration a second collar associated with a suction tube, the tip is configured for insertion into a passageway; the stop being configured for detachable connection to the lower portion of the bulb body when in the first configuration; and the suction tube including the second collar, a tube portion and an adaptor, the second collar is disposed at a first end of the suction tube and being adapted to be coupled to the lower portion of the bulb body, the adaptor is configured to adapt to a human mouth to enable suction to be applied at the adaptor.

Abstract: A system or device for providing medical suction, particularly for intubating patients, wherein the system or device helps prevent clogging from solids dispersed in the liquid to be suctioned. This device will allow the user to effectively clear an airway or other region of the patient while minimizing the occurrence of clogs and providing for the effective and expedited unclogging of the device without the necessity of removing the device from the patient or requiring two hands to unclog.

Abstract: A system for facilitating fluid connection between cannulae and a blood pump. The system includes a cannula having a distal end adapted to be in fluid communication with the circulatory system and a proximal end configured to couple to an inlet of the blood pump. Further included is a tunneling device configured to be inserted into a body of a patient to direct the proximal end of the cannula adjacent to the inlet and including a second connecting structure. Further included is a plug which has a first plug part and a second plug part. The first plug part includes a second connecting structure, the first and second connecting structures being selectively engageable. The second plug part is configured to be inserted in the proximal end of the cannula. The first and second plug parts are selectively disengageable to allow in situ disconnection between the cannula and tunneling device.

Abstract: There is disclosed apparatus and methods for providing a reserve power source for a ventricular assist device. In an embodiment, the apparatus includes a primary power source for powering the device, and a controller housing having a reserve battery for powering the device when the primary power source provides inadequate power, and the controller housing configured for use externally of the patient with a percutaneous cable to the device. In another embodiment, a method includes powering the device with a primary power source, monitoring power provided to the device, powering the device when the power is monitored as inadequate to the device with a reserve power source disposed within a controller housing, the device disposed subcutaneously within a patient, the controller housing disposed externally of the patient, and the device and the controller housing connected by a percutaneous cable. Other embodiments are also disclosed.

Abstract: Discussed is a method of extracting high-concentration plasma from whole blood, the method including: collecting whole blood in a first syringe; connecting a centrifugation tube to the first syringe and centrifuging the whole blood; separating the centrifugation tube containing red blood cells collected therein; discharging buffy coat from the first syringe; connecting the first syringe and a second syringe to a pair of inlets of a membrane filter; applying pressure to the first syringe to introduce the plasma into the membrane filter, and introducing the plasma from the second syringe into the membrane filter; repeating said applying and introducing steps; and collecting a high-concentration plasma containing components that are larger than a predetermined particle diameter and remain in a cavity portion of a membrane of the membrane filter without passing through the membrane.

Abstract: The interface between nanotechnology and biological systems is used to synthetically replicate the body's vital, innate, immune functions with targeted precision. Through the creation and use of complexed nanodiamonds (or other particles) with capture agents in a flow-through return apparatus or in an analytic/diagnostic tool, the invention provides individualized treatment of blood-borne pathogens and disease spectrums and rapid, individualized diagnostics. The invention can be used, for example, to clear blood-borne pathogens during initial infections prior to tissue sequestration in real time, to decrease overwhelming numbers of bacterial/viral/cytokine load during life threatening infectious conditions, to super sensitize the immune system to a variety of conditions-cancer markers, vaccinates, etc.

Abstract: A system for cleansing a patient's ear is disclosed. The system includes a control unit, a portable applicator, and a liquid reservoir. The liquid reservoir includes a heater. The control unit includes controls for maintaining the temperature of the liquid in the reservoir within certain limits, for limiting the pressure of the liquid, and for varying the flow rate and pressure of the liquid. The portable applicator includes a hand piece, a nozzle connected to the fluid source and mounted on the hand piece, and a trigger for providing a flow control signal to the control unit.

Abstract: A cartridge system for delivery of medicament includes as membrane placed between two disk magnets that are housed within pump body inserts. The pump body inserts having flow channels and fluid openings are between two inlet/outlet members. The inlet/outlet members each having a fluid outlet component and fluid openings are securely engaged to two reservoirs containing fluid medicaments.

Abstract: An infusion pump assembly includes an enclosure assembly. A reservoir assembly is positioned at least partially within the enclosure assembly and is configured to contain an infusible fluid. A pump assembly is positioned at least partially within the enclosure assembly and is configured to effectuate the dispensing of the infusible fluid contained within the reservoir assembly. Processing logic is positioned at least partially within the enclosure assembly and is configured to control the pump assembly. A removable cover assembly is configured to releasably engage the enclosure assembly. A combination of the removable cover assembly and at least a portion of the enclosure assembly defines a power supply cavity configured to prevent a removable power supply assembly from being reverse-polarity electrically coupled to the processing logic.

Abstract: An embodiment of a fluid infusion device includes a fluid pump mechanism having a rotor and a stator. The rotor includes a reference surface and a cam element rising from the reference surface, and the stator includes a cam element having a stator cam surface. The cam elements cooperate to axially displace the rotor as a function of angular position of the rotor. A biasing element provides force to urge the cam elements together. A drive motor actuates the rotor to pump medication fluid from a fluid cartridge module to a body, via a subcutaneous conduit. A detection circuit processes axial and angular position data of the rotor, and determines that an upstream occlusion has occurred based on detectable characteristics of the axial and angular position data.

Abstract: A user-wearable patch pump system for delivery of insulin or other medicament can include a patch pump having a reusable drive unit and a replaceable and refillable cartridge. The cartridge can selectively attach to and be detached from the drive unit. The cartridge can initially be inserted onto the drive unit in a first orientation at an angle to the drive unit and then be rotated to align the cartridge with the drive unit and lock the cartridge in place on the drive unit to form the patch pump.

Abstract: Implantable infusion devices and systems with side port access detection capability and methods of detecting side port access.

Abstract: The invention relates to a lubricant coating (5) for a medical injection device (1), comprising successively: —a bottom layer (50) in contact with the medical device surface (21) of the container to be lubricated, comprising a mixture of cross-linked and non-cross-linked poly-(dimethylsiloxane), —an intermediate layer (51) consisting essentially of oxidized poly-(dimethylsiloxane) and having a thickness comprised between 10 and 30 nm and, —a top layer (52) consisting essentially of non-cross-linked poly-(dimethylsiloxane) and having a thickness of at most 2 nm. The invention also relates to a medical injection device comprising such a lubricant coating, and a manufacturing process for said coating.

Abstract: The present invention relates to a display arrangement for a drug delivery device, comprising: a first display member comprising numerous surface portions having at least two different but interrelated appearances and being alternately arranged along a first direction, and a second display member comprising a light modulating structure to modulate visible light emanating from the first display member, wherein first and second display members are movably disposed relative to each other along the first direction to simultaneously reveal and/or to conceal at least two surface portions of interrelated appearance.

Abstract: A skin engagement member is provided herein for use with a needle assembly or a medical injector to minimize irritation of a patient's skin surrounding an injection site during injection by a needle of the needle assembly or the medical injector. The skin engagement member includes: a body; a surface defined on the body for engaging the patient's skin during injection by the needle; an aperture formed through the body configured to permit passage therethrough of the needle; and, rotatable mounting features for rotatably mounting the body to the needle assembly or the medical injector such that the surface, while engaging the patient's skin, is rotatable about the aperture.

Abstract: A wearable infusion pump assembly. The wearable infusion pump assembly includes a reservoir for receiving an infusible fluid and a fluid delivery system configured to deliver the infusible fluid from the reservoir to an external infusion set. The fluid delivery system includes a controller, a pump assembly for extracting a quantity of infusible fluid from the reservoir and providing the quantity of infusible fluid to the external infusion set, the pump assembly comprising a pump plunger, the pump plunger having distance of travel, the distance of travel having a starting position and an ending position, at least one optical sensor assembly for sensing the starting position and ending position of the pump plunger distance of travel and sending sensor output to the controller, and a first valve assembly configured to selectively isolate the pump assembly from the reservoir, wherein the controller receives the sensor output and determines the total displacement of the pump plunger.

Abstract: Disclosed is an inhaler and a method for using the inhaler for the inhalation of a formulation from a carrier. The carrier contains the formulation in a receptacle and is set oscillating by an air current. An improved or defined delivery and nebulisation of the preferably powdered formulation is made possible by the fact that the carrier is set oscillating in defined manner, the formulation is dispensed through a cover element having three to five holes and/or the air current flows onto a fin associated with the carrier and flows past at least substantially only one flat side of the carrier.

Abstract: An inhaler device for pulmonary delivery of at least one substance from a drug dose cartridge to an inhaling user, including: a first conduit for conducting a carrier airflow to a proximal opening of a mouthpiece for use by the user; a holder configured to position the dose cartridge within the carrier airflow; and a second conduit for conducting a shunting airflow to the mouthpiece without passing through the dose cartridge position. A controller connected to a valve controls a rate of carrier airflow, for example by controlling the shunting airflow, based on a sensor indication of airflow rate and a target airflow profile.

Abstract: A non linear, medicated aerosol holding and delivery chamber without sealing valves at the aerosol inlet and outlet ends. There is a low pressure actuated, vacuum relief, drain check valve at the bottom end of the chamber and an overpressure relief valve at the top end adjacent the mouthpiece opening. The vacuum relief, drain check valve has a radial support plate beneath it that allows for the creation of a vortex in the aerosol plume. The drain check valve also provides for the complete return of any condensed aerosol to the nebulizer when closed. The overpressure relief valve efficiently allows dispelling of the patient's air. Both valves aid in the decrease of the MMAD of the medicated aerosol particles. There is no truly enclosed volume defined by the body of the chamber as the mouthpiece is open into the top of the chamber body, free of any valves.

Abstract: This disclosure describes systems and methods for providing an optimized proportional assist breath type during ventilation of a patient. The disclosure describes a novel breath type that delivers a target airway pressure calculated based on a desired patient effort range to a triggering patient.